Monopost Unidose (Latanoprost)

Latanoprost, the active ingredient in Monopost Unidose, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Monopost Unidose as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost belongs to the prostaglandin analog class and is used to manage conditions that require reduction of intra‑ocular pressure. Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage and preserve visual field. Ocular hypertension: lowers elevated eye pressure to prevent progression to glaucoma.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia: mild conjunctival injection after instillation. - Increased eyelash growth: longer, thicker lashes may develop. - Iris pigmentation change: gradual darkening of the iris color. - Eye irritation or foreign‑body sensation: transient discomfort.

Serious or Rare Side Effects: - Uveitis or intraocular inflammation: requires immediate ophthalmic evaluation. - Macular edema: rare swelling of the central retina that can affect vision. - Severe allergic reaction: including swelling, itching, or rash around the eye. - Vision loss: abrupt decrease in visual acuity warrants urgent care. - Persistent eye pain: may indicate a serious ocular condition.

Before using Latanoprost, patients and clinicians should consider several safety measures. Monitor IOP: schedule regular intra‑ocular pressure checks to assess efficacy. Assess for ocular infection: avoid use if active conjunctivitis or keratitis is present. Avoid use in patients with active intraocular inflammation: may exacerbate the condition. Caution in patients with a history of uveitis: increased risk of flare‑ups. Pregnancy: safety category unknown; prescribe only if potential benefit justifies the risk. Store at below 25°C: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, influencing pressure control or tolerability.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: additive IOP lowering may cause excessive reduction. - Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost efficacy. - Systemic carbonic anhydrase inhibitors: potential interference with intra‑ocular pressure regulation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined effect may lead to overly low IOP; monitor pressure. - Alpha‑agonist eye drops: possible additive pressure‑lowering; adjust therapy as needed. - Systemic antihistamines: may cause dry eye; assess ocular comfort regularly.